UNSPSC 51343818: Nevirapine and lamivudine/tenofovir DF

This classification denotes a combination drug for treatment of HIV. This is for copackaged product. The first component, NEVIRAPINE, has US FDA Unique Ingredient Identifier of 99DK7FVK1H. The second component, LAMIVUDINE, has US FDA Unique Ingredient Identifier of 2T8Q726O95. The third component, TENOFOVIR DISOPROXIL FUMARATE, has US FDA Unique Ingredient Identifier of OTT9J7900I.

UNSPSC 51343818 Nevirapine and lamivudine/tenofovir DF is a Commodity code representing antiretroviral pharmaceuticals for HIV treatment. Recent state and local opportunities show minimal direct procurement under this code; the most proximate related activity involves broader pharmaceutical and medical supply solicitations by county health departments, fire departments, and forensic laboratories acquiring HIV-related or general pharmaceutical inventories as part of larger health systems or emergency medical services contracts. Issuing bodies include county governments (Seminole County, Florida; Pinellas County, Florida; Bernalillo County, New Mexico) and municipal fire departments (City of Tucson, Arizona), with activity concentrated in Florida, Arizona, and New Mexico. The code itself does not appear in recent solicitations as a standalone drug procurement; instead, state and local buyers acquire antiretroviral medications as components of comprehensive pharmaceutical supply agreements, clinical wellness programs, or forensic laboratory reference standards when HIV-related testing or treatment services are in scope.

No formal recent solicitations specifically name nevirapine or lamivudine/tenofovir DF as a line-item procurement. The closest related opportunity is Seminole County, Florida's June 2026 IFB for Naloxone and Drug Deactivation Systems (1,900 units of Naloxone annually), which addresses opioid response rather than HIV treatment; Pinellas County's April 2026 ITQ for forensic drug standards procurement (131 line items for toxicology analysis); and the City of Tucson Fire Department's June 2026 RFP for BLS/ALS Pharmaceuticals and Supplies, which encompasses 251 line items of emergency medical products but does not itemize antiretroviral drugs. Geographic activity concentrates in Florida (Seminole, Pinellas counties) and Arizona (Tucson), with secondary activity in New Mexico (Bernalillo County). Without recent standalone solicitations or cooperative-purchasing vehicle awards naming these specific antiretrovirals, the code shows dormant procurement activity at the state and local level as of mid-2026.